Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

a.tenuis) 10hep solution for skin prick test (alk-abello ltd - alternaria alternata (a.tenuis) allergen extract - solution for skin-prick test

Bandaríkin - enska - NLM (National Library of Medicine)

alk-abello, inc. - alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h), aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48), cladosporium cladosporioides (unii: 4zwy20gtgo) (cladosporium cladosporioides - unii:4zwy20gtgo), penicillium chrysogenum var. chrysogenum (unii: 3y1pe1gcig) (penicillium chrysogenum var. chrysogenum - unii:3y1pe1gcig) - these products are for diagnostic use only. diagnostic allergenic extracts are indicated for use in skin testing to establish the clinical relevance of specific allergens to which the patient has been exposed. by measuring skin test response, the physician may assess the degree of sensitivity that patients have to the allergens. for extracts standardized in au and bau, see individual directions for use. allergenic extracts for diagnostic use only of coffee, mosquito, cottonseed, and flaxseed have not been shown by adequate data to be safe and effective for therapeutic use. patients on beta blockers can be non-responsive to beta agonists that may be required to reverse a systemic reaction (also, see boxed warning statement and adverse reactions ). the physician should carefully weigh the benefit derived from skin testing vs. the risk to the patient should a systemic reaction arise. patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater

Bandaríkin - enska - NLM (National Library of Medicine)

alk-abello, inc. - alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h), aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48), cladosporium cladosporioides (unii: 4zwy20gtgo) (cladosporium cladosporioides - unii:4zwy20gtgo), penicillium chrysogenum var. chrysogenum (unii: 3y1pe1gcig) (penicillium chrysogenum var. chrysogenum - unii:3y1pe1gcig) - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

Bandaríkin - enska - NLM (National Library of Medicine)

alk-abello, inc. - alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h), aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48), cladosporium cladosporioides (unii: 4zwy20gtgo) (cladosporium cladosporioides - unii:4zwy20gtgo), penicillium chrysogenum var. chrysogenum (unii: 3y1pe1gcig) (penicillium chrysogenum var. chrysogenum - unii:3y1pe1gcig) - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - alternaria alternata, quantity: 0.5 ml (equivalent: alternaria alternata, qty 10 mg/ml); phoma herbarum, quantity: 0.5 ml (equivalent: phoma herbarum, qty 10 mg/ml); cochliobolus heterostrophus, quantity: 0.25 ml (equivalent: cochliobolus heterostrophus, qty 5 mg/ml); aspergillus fumigatus, quantity: 0.1 ml (equivalent: aspergillus fumigatus, qty 3 mg/ml); aspergillus terreus, quantity: 0.1 ml (equivalent: aspergillus terreus, qty 3 mg/ml); aspergillus nidulans, quantity: 0.1 ml (equivalent: aspergillus nid - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Bandaríkin - enska - NLM (National Library of Medicine)

nelco laboratories, inc. - aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48) - aspergillus fumigatus 0.05 g in 1 ml - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

Bandaríkin - enska - NLM (National Library of Medicine)

nelco laboratories, inc. - aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48) - aspergillus fumigatus 0.1 g in 1 ml - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

Bandaríkin - enska - NLM (National Library of Medicine)

nelco laboratories, inc. - aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48) - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

Bandaríkin - enska - NLM (National Library of Medicine)

nelco laboratories, inc. - aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48) - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

Bandaríkin - enska - NLM (National Library of Medicine)

nelco laboratories, inc. - aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48) - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t